Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients

NAUnknownINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Nimotuzumab and TP regimen

"1. TP Regims:Paclitaxel Liposome,135mg/m2,d1;Carbopatin(AUC=5) d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment, 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."

DRUG

TP regimen

TP Regimen:Paclitaxel Liposome,135mg/m2,d1;Carbopatin(AUC=5) d2, 3 weeks/cycle,for 4 cycles.

Trial Locations (1)

Unknown

RECRUITING

Tianjian Medical University Cancer Institue and Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Biotech Pharmaceutical Co., Ltd.

OTHER

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER